Table 3. Sensitivity analysis: Harvard model (all outcomes)*.
| Strategies | Base case (all outcomes) | Imperfect CC screen† | Cost per life-year | 3-dose HPV vaccine cost = $529 | 3-dose HPV vaccine cost = $704 | 20-year lag time for other HPV-related cancers‡ | 40-year lag time for other HPV-related cancers‡ |
|---|---|---|---|---|---|---|---|
| Vacc to age 30|| | dom | dom | dom | dom | dom | dom | dom |
| Vacc to age 35 | dom | dom | dom | dom | dom | dom | dom |
| Vacc to age 40 | dom | $245,200 | dom | dom | dom | dom | dom |
| Vacc to age 45 | $440,600 | $363,800 | $672,800 | $340,900 | $460,400 | $574,500 | $651,300 |
* Values represent incremental cost-effectiveness ratios, in terms of costs per quality-adjusted life year (QALY) gained, compared to the next less costly, nondominated strategy; status quo vaccination is the baseline strategy; “dom” indicates dominated strategies that are less costly and less cost-effective (i.e., weakly dominated) than an alternative strategy. All HPV-related outcomes (except RRP) were included.
† Imperfect cervical cancer screen reflects patterns of screening, diagnosis, and precancer treatment as observed in the New Mexico HPV Pap Registry (see Methods and S1 Text for details).
‡ Minimum 20- or 40-year lag time from HPV infection to cancer for non-cervix HPV-related cancers.
|| Vaccination to age 30 compared against current vaccination.